Prevention of Syncope (fainting) Trial 11
Summary
About 20% of adults faint regularly. No treatments are proven useful in executed clinical trials. This is a study to test the theory that Ondansetron reduces the time to a recurrence of faint in a TILT test. In this study half the patients will receive Ondansetron the night before and the morning of the study day ( TILT Table test) the other half will receive a Placebo. you need to fill in two surveys. No follow-up needed after the study day.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 18 to 99
Inclusion criteria:
1. ≥1 faints in the year preceding enrolment
2. Vasovagal Syncope
3. Age ≥ 18 years
Exclusion criteria:
(1) other causes of syncope, such as ventricular tachycardia, complete heart block, orthostatic hypotension or hypersensitive carotid sinus syndrome
(2) an inability to give informed consent
(3) important valvular, coronary, myocardial or conduction abnormality or significant arrhythmia
(4) hypertrophic cardiomyopathy
(5) a permanent pacemaker
(6) a seizure disorder
(7) hypertension defined as >160/90 mm Hg
(8) pregnancy
(9) lactating women
(10) glaucoma
(11) medications with known effects on BP
(12) Known hypersensitivity to ondansetron and related medications
(13) other factors which, in the investigator’s opinion, would prevent the subject from completing the protocol.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Rasha Hamzeh Email: rasha.hamzeh1@ucalgary.ca Phone number:403-220-8897
Principal investigator:
Robert Stanley Sheldon
Clinical trial:
Yes
REB-ID:
REB23-0198